MeiraGTx Holdings PLC $MGTX Position Decreased by Erste Asset Management GmbH

Erste Asset Management GmbH lowered its holdings in MeiraGTx Holdings PLC (NASDAQ:MGTX) by 10.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 709,702 shares of the company’s stock after selling 80,000 shares during the period. Erste Asset Management GmbH’s holdings in MeiraGTx were worth $5,855,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MGTX. BNP Paribas Financial Markets boosted its holdings in MeiraGTx by 43.8% during the second quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock worth $31,000 after buying an additional 1,466 shares in the last quarter. State of Alaska Department of Revenue bought a new position in shares of MeiraGTx in the third quarter valued at $33,000. Tower Research Capital LLC TRC lifted its position in shares of MeiraGTx by 390.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock valued at $57,000 after acquiring an additional 7,005 shares during the last quarter. Levin Capital Strategies L.P. acquired a new stake in shares of MeiraGTx during the 2nd quarter valued at $163,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of MeiraGTx during the 3rd quarter worth $189,000. 67.48% of the stock is owned by institutional investors and hedge funds.

MeiraGTx Trading Down 1.3%

NASDAQ:MGTX opened at $7.56 on Friday. The company has a debt-to-equity ratio of 26.29, a current ratio of 0.22 and a quick ratio of 0.22. MeiraGTx Holdings PLC has a fifty-two week low of $4.55 and a fifty-two week high of $9.73. The stock’s 50-day moving average is $7.69 and its two-hundred day moving average is $7.97. The stock has a market cap of $608.50 million, a PE ratio of -3.58 and a beta of 1.37.

Analyst Ratings Changes

A number of brokerages have recently issued reports on MGTX. HC Wainwright assumed coverage on MeiraGTx in a research report on Monday, November 24th. They set a “buy” rating and a $20.00 target price on the stock. Zacks Research lowered shares of MeiraGTx from a “hold” rating to a “strong sell” rating in a research note on Friday, January 30th. Piper Sandler raised their target price on shares of MeiraGTx from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Chardan Capital restated a “buy” rating and set a $35.00 price target on shares of MeiraGTx in a report on Tuesday, November 11th. Finally, Royal Bank Of Canada upped their price target on shares of MeiraGTx from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, MeiraGTx presently has an average rating of “Moderate Buy” and an average target price of $26.00.

About MeiraGTx

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.